Relonchem Ltd receives Marketing Authorisation for the product Levetiracetam Relonchem 100 mg/mL Oral Solution

Marksans Pharma Limited (Reuters: MARK.BO; Bloomberg: MRKS IN; NSE: MARKSANS; BSE: 524404) announced that its wholly owned subsidiary Relonchem Limited has has received Marketing Authorization for the product Levetiracetam Relonchem 100 mg/mL Oral Solution from UK MHRA.

The product will be manufactured at the Group's UK manufacturing facility.

Shares of Marksans Pharma Limited was last trading in BSE at Rs. 164.60 as compared to the previous close of Rs. 168.45. The total number of shares traded during the day was 205664 in over 2665 trades.

The stock hit an intraday high of Rs. 171.50 and intraday low of 163.85. The net turnover during the day was Rs. 34499784.00.

Source : Equity Bulls

Keywords

MarksansPharma INE750C01026 Relonchem MarketingAuthorization UKMHRA LevetiracetamRelonchem